Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS235 in Pulmonary Arterial Hypertension
NCT07143448Phase 2Recruiting
- Sponsor
- 35Pharma
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of HS235 in pulmonary arterial hypertension (PAH), sponsored by 35Pharma. Started Aug 2026; status: recruiting.
02
Drugs
HS235
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07143448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143448.